TABLE 1

Characteristics of Eligible Studies

Reference	Year	Design	Sample (n)	Primary (n)	Type of lymphoma	Mean or median age (y)	Male (%)	BMB site	¹⁸F-FDG dose (MBq)	Measures	Any blinding stated
Naumann et al. (7)	2004	Prospective	88	77	HD	34	65	NR	300–370	SUV	No
Elstrom et al. (9)	2003	Retrospective	105	NR	HD, NHL	NR	NR	NR	2.516/kg	SUV	No
Hoffmann et al. (10)	2003	Retrospective	21	21	NHL	NR	NR	NR	300–380	Qualitatively	Yes
Hong et al. (11)*	2003	Prospective	30	21	HD, NHL	49	63	Bilateral	370	Qualitatively	Yes
Sasaki et al. (12)	2002	NR	30	NR	HD, NHL	60	61	NR	270.6, mean	Qualitatively	Yes
Montravers et al. (13)	2002	NR	7	7	HD	13	NR	NR	2–3/kg	Qualitatively	No
Wirth et al. (14)	2002	Retrospective	39	NR	HD, NHL	48	62	NR	NR	Qualitatively	No
Jerusalem et al. (15)	2001	Prospective	42	26	NHL	62	NR	Bilateral	200–300	Qualitatively	Yes
Jerusalem et al. (16)	2001	Prospective	33	24	HD	33	39	Bilateral	200–300	Qualitatively	Yes
Buchmann et al. (17)	2001	Prospective	52	52	HD, NHL	41	54	Unilateral	390, mean	Qualitatively	Yes
Partridge et al. (18)	2000	Retrospective	24	NR	HD	38	48	Unilateral	350	Qualitatively	Yes
Moog et al. (8)	1998	Prospective	78	78	HD, NHL	38	46	Bilateral, unilateral	270, mean	Qualitatively	Yes
Carr et al. (19)	1998	Prospective	38	38	NHL	NR	NR	Unilateral	350	Qualitatively	Yes

↵* Includes 21 patients at initial staging and 9 patients at restaging after treatment.
NR = not reported; SUV = standardized uptake value.